

Jaguar Health, Inc.

(NASDAQ: JAGX)

Overview – December 2025




Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Company”), Napo Pharmaceuticals, Inc. and Napo Therapeutics (formerly known as “Napo EU”) to develop and commercialize crofelemer in Europe for HIV-related diarrhea, short bowel syndrome, congenital diarrheal disorders, and other indications; expectations related to the timing of the commercial launch of products in any market; the expectation that Magdalena Biosciences will leverage Jaguar’s proprietary medicinal plant library and Filament Health’s proprietary drug development technology; the expectation that US\$1,000,000 will be invested in Magdalena Biosciences by One Small Planet; the expectation that Magdalena Biosciences may develop a potential plant-based alternative drug for adult ADHD or other indications that is both safe and efficacious; Jaguar’s plans to pursue additional business development deals; plans to expand the geography for commercialization of crofelemer; statements related to the powder formulation of crofelemer, NP-300, and the timing of the initiation, completion, results, and publication of Phase 2 studies, Phase 3 studies, proof-of-concept studies, field studies, investigator-initiated trials, sponsored studies, and other studies; statements about crofelemer’s possible eligibility for, and possible future participation in, the European Medicines Agency’s (EMA) PRIME program, the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy program, the FDA’s priority review program(s), and early patient access programs; Jaguar’s expectation that the currently estimated US metastatic breast cancer population qualifies as an orphan population, Jaguar’s expectation that potential pathways exist to facilitate crofelemer’s approval for cancer treatment-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies, Jaguar’s expectation that it will initiate an expanded access program for breast cancer patients with CTD, Jaguar’s expectation that Napo Pharmaceuticals will conduct a clinical trial of crofelemer for treatment of CTD in patients with metastatic breast cancer; statements about the planned submission of Investigational New Drug (IND) applications, New Drug Applications (NDA) and supplemental NDAs to FDA; statements about plans to pursue a Priority Review Voucher (PRV) and the potential value of a PRV; statements about the possible market size/potential of indications; and statements about expected milestones appearing on the list of “Upcoming Milestones”, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Please see the risk factors identified in our Annual Report on Form 10-K and our other filings with the U.S. Securities and Exchange Commission. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Readers are also advised that our projected sales do not take into account the royalties and other payments we will need to make to our licensors and strategic partners. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

What's Different?????

- The classic definition of insanity: Doing the same thing over and over again and expecting a different result
- Equally crazy—changing the approach and expecting to get the same results



What We Do: Develop New Ways and Novel Plant-Based Medicines to Treat Gastrointestinal Disorders

From Tree to Bottle

Crofelemer was discovered through the science of ethnobotany



Canalevia®-CA1 is conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs



Mytesi (crofelemer 125mg delayed-release tablets) is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy

Mytesi (125 mg Crofelemer Delayed-Release Tablets): Pipeline in a Product

PRODUCT	INDICATIONS EVALUATED	DEVELOPMENT STAGE					
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COMMERCIALIZED (US)	GEOGRAPHIC FOCUS OF CLINICAL STUDIES
Mytesi (crofelemer)	Noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy						US
Crofelemer	Cancer therapy-related diarrhea (CTD)						US
			Subject of Phase 3 OnTarget trial				

Proof-of-Concept & Phase 2 Clinical Studies


PRODUCT	INDICATIONS EVALUATED	DEVELOPMENT STAGE					
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COMMERCIALIZED (US)	GEOGRAPHIC FOCUS OF CLINICAL STUDIES
Crofelemer	IBS - Diarrhea Predominant (IBS-D)				<i>Oct 2024: Poster at American College of Gastroenterology Annual Meeting</i>	US	
Crofelemer	Chronic idiopathic diarrhea				<i>Oct 2024: Poster at American College of Gastroenterology Annual Meeting</i>	US	
Crofelemer	Symptomatic relief of diarrhea from the bacterium that causes cholera				<i>Data presented at 2008 NIAID Annual Meeting in Japan</i>	US	

Novel Crofelemer Powder for Oral Solution – New NDA Planned

PRODUCT	INDICATIONS EVALUATED	DEVELOPMENT STAGE					
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	COMMERCIALIZED (US)	GEOGRAPHIC FOCUS OF CLINICAL STUDIES
Highly concentrated formulation of lyophilized crofelemer	Pediatric microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD)				<i>Initial results presented Nov 8, 2025, at NASPGHAN</i>		US, EU & Middle East/North Africa (MENA)
Highly concentrated formulation of lyophilized crofelemer	Short bowel syndrome with intestinal failure (SBS-IF)				<i>Pediatric initial results presented Nov 8, 2025, at NASPGHAN</i>		EU & US

Catalysts and Robustness: Financially, Clinically, Partnering

- **Financial robustness:** Commercial stage company, with ~\$12 million annual net revenue
 - 4% net revenue increase in Q3 vs Q2 2025
- **Clinical robustness/near-term catalysts:**
 - **Completed FDA meetings in 2025 to clarify planned pathways to bring two products to fileable data:**
 - **Mytesi sNDA for CTD**
 - SS Phase 3 data in breast cancer from OnTarget pivotal trial
 - **Crofelemer lyo product for MVID IF**
 - **Groundbreaking POC data**
- **Partnering Robustness:** Global unencumbered rights to crofelemer for business development / collaborations:
 - Mytesi (HIV expansion to CTD and IBS)
 - Orphan IF indications
 - Canalevia expansion beyond CID



Dec 9, 2025: FDA Approves Renewal of Canalevia-CA1 for Chemotherapy-Induced Diarrhea (CID) in Dogs


- Conditional approval extended through December 2026 for the treatment of CID in dogs
- Under conditional approval, FDA requires a confirmatory trial within 5 years to for full approval of the drug
- Jaguar's CID confirmatory effectiveness trial expected to conclude in February 2026
- **Sep 2025:** Potential \$250k FDA grant to fund confirmatory trial



Summary of May 2025 FDA Meeting for Mytesi CTD

OnTarget data is “invaluable... first-of-its-kind study”

- Lead of participation: Patient advocates shared their raw and personal experience
- Messaging
 - The results are supportive of an efficient/expeditious pathway for a patient population with metastatic breast cancer on targeted therapy
 - Currently US metastatic breast cancer population (~150k)
 - Filed for ODD
 - Agreement for confirmatory random withdrawal trial: Risk reduction due to: (i) Treatment study; (ii) Enrollment criteria more severe diarrhea; (iii) Failure (on placebo) is a win for crofelemer/no rescue med interference
 - Expanded access “immediately” for patients who don’t qualify for enrollment
 - Next steps:
 - File Final Study Report for OnTarget
 - Complete survey of relevance of reduction in diarrhea / loose watery stools
 - Outline of proposed mBC treatment study



Napo Pharmaceuticals' *Make Cancer Less Shitty* Patient Engagement Program—Including Regulatory Activity



“ If you ask me what’s your worst side effect, I’m going to ask you what day of the week is this? Because tomorrow is different, the next day is different, tonight is different. This morning is different. ”

— Person Living With Metastatic Breast Cancer

A NEGLECTED PROBLEM

People with cancer experience numerous challenges – including **treatment-related side effects** – that can impact their quality of life (QoL). Supportive care is critical to addressing these challenges.

In a study of patient-reported chemotherapy side effects, participants reported having at least one debilitating side effect.¹

6 in 10

81% of cancer survivors reported they had unmet supportive care needs and reported dissatisfaction with current supportive care services.²

In a survey of oncology community stakeholders (researchers, nurses, medical oncologists, administrators, surgical and radiation oncologists, patient advocates, and nonphysician providers), patient QoL was ranked the most important metric over survival, access to care, and cost.³

There remains an **urgent need** to enhance supportive care as part of overall cancer care to best protect the dignity and QoL of those living with cancer.




¹ Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS One. 2017 Oct 10;12(10):e0184360

² Moore TH, King AJ, Evans M, Sharp D, Persad R, Huntley AL. Supportive care for men with prostate cancer: why are the trials not working? A systematic review and recommendations for future trials. Cancer Med. 2015 Aug;4(8):1240-51

³ Casey J. Allen et al. Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey. JCO Oncol Pract 19, 932-938(2023)


Diarrhea Rates Among Breast Cancer Targeted Therapies*



*Not inclusive of all potential therapies. Rates are for any grade diarrhea.

Jaguar Reported Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on July 23, 2024

- A growing and urgent unmet medical need exists for novel non-opioid chronic agents to treat CTD
- Unprecedented trial included patients, prophylaxis, with 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies
- Study did not meet prespecified analysis of primary endpoint for all tumor types
- **Phase 3 data with significant results in prespecified subgroup of adult patients with breast cancer**
 - Patients with CTD 40% more likely to discontinue chemotherapy or targeted therapy than those without CTD¹
 - The cost of care of CTD patients is estimated to be 2.9 times higher than for patients who are not experiencing CTD²
 - Strong patient advocacy




¹ Pablo C. Okhuysen, M.D. *Impact of Cancer-Related Diarrhea on Changes in Cancer Therapy Patterns: Real World Evidence*

² Eric Roeland, M.D., FAAHPM. *Healthcare Utilization and Costs Associated with Cancer-Related Diarrhea*

Short Bowel Syndrome: Loss of Bowel with Quality-of-Life Changes

- **SBS:** Catastrophic loss of bowel (normal 15-25 feet to 5 or less feet)
- **SBS with Intestinal Failure (SBS-IF):** Body is unable to absorb enough nutrients
- Lifelong total parenteral nutrition (TPN/PS)
- Risk of liver/kidney/cognitive function
 - No “standard of care” drug intervention
- **Key endpoint demonstrating benefit**
 - **Reduction in TPN/PS**
 - Enhanced urine output
 - Reduction in stool volume
- **Novel highly concentration liquid formulation**



Microvillus Inclusion Disease (MVID): An Ultrarare Congenital Diarrheal Disorder (CDD)

- MVID is an ultrarare CDD that affects newborns and children and leads to significant morbidity and mortality from **severe secretory diarrhea, intestinal failure, lifelong total parenteral nutrition (TPN)**
- **Intestinal Failure:** Body is unable to absorb nutrients
- Lifelong total parenteral nutrition (TPN/PS)
- Risk of liver and kidney function problems/neurodevelopmental delay
- **Key endpoint demonstrating benefit**
 - **Reduction in TPN/PS**
 - Enhanced urine output
 - Reduction in stool volume
- **Novel highly concentrated liquid formulation**



* Adverse events could negatively affect the timeliness of submitting the Investigational New Drug (IND) application. There is a probability that the FDA may not approve Company's IND application.

Presented April 26, 2025: Initial Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition (TPN) in Patients with MVID and SBS-IF – Potential to Modify Disease Progression in Intestinal Failure Patients

- **Novel liquid formulation of crofelemer** reduced required TPN in patients due to MVID and SBS **by up to 27% and 12.5% respectively**
 - Current reduction in MVID: 37%
- Crofelemer **reduced stool volume output and/or frequency of watery stools, and increased urine output**—indicator of improved nutrient oral absorption
- Patient relapsed when crofelemer discontinued
- Initial results **presented at April 2025 Annual ELITE PED-GI Congress**
- **Modify disease progression** in MVID and SBS-IF patients and potentially qualify for **PRIME** designation for MVID—accelerated full approval and pricing by EMA; potential Breakthrough Therapy designation in US
 - Potential for approval in single digit number of patients

Replay Link to Jaguar's April 30, 2025 Investor Webcast About the Initial Study Results:

https://viaid.webcasts.com/starthere.jsp?ei=1718118&tp_key=02fe2f82c4



The [Annual Elite Ped-GI Congress](#) is designed to provide high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders.

Met with FDA to Discuss Expedited Regulatory Pathways for Crofelemer for MVID;

Abstract Presented at NASPGHAN 2025 Annual Meeting

- Napo met with **FDA** to discuss the company's ongoing clinical development program for crofelemer for treatment of MVID
 - Groundbreaking POC data shows crofelemer treatment in MVID has the potential to modify disease progression in intestinal failure and transform patients' lives
 - Oct 2, 2025: Jaguar completed meeting with FDA for advice on expedited development pathway for ongoing crofelemer trial for potential approval for treatment of MVID
- Members of Napo's **Scientific Advisory Board** joined Napo and Jaguar representatives at the meeting
- Initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient **by up to 37%**
- Abstract describing above presented at the [North American Society for Pediatric Gastroenterology, Hepatology and Nutrition \(NASPGHAN\) Annual Meeting](#) Nov 8, 2025, in Chicago



A Global Opportunity

- SBS Global Patient Population ~40,000
- Global SBS market: Estimated value of \$2 billion in 2024 and expected to reach **\$6.4 billion by 2030**¹
- Gattex (teduglutide; growth hormone):
 - Estimated share of US market: ~1-2%²
 - Annual cost in US: ~\$485,400³
 - Multiple biosimilars in development by other companies
 - Zealand Pharma Complete Response Letter
 - **“Gattex can make abnormal cells that are already in your body grow faster. There is an increased risk that abnormal cells could become cancer.”** Source: Gattex Important Safety Information statement
- **Crofelemer unique patient population:**
 - **Cancer patients**
 - **Surgical patients with required bowel adaptation**
 - **AND can be used with GH- opportunity for chronic SOC**



¹ <https://www.globenewswire.com/news-release/2025/02/12/3024819/28124/en/Growth-Trends-in-the-Short-Bowel-Syndrome-SBS-Market-2025-2030-Growth-of-Home-Healthcare-Specialty-Clinics-and-Telemedicine-Strengthens-Business-Case-for-SBS-Treatments.html>

² Jaguar estimate based on an estimated US SBS population of 10,000-20,000 people (www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/short-bowel-disease-crohns.pdf)

³ 10 priciest drugs in America (<https://www.benefitspro.com/2020/08/24/10-priciest-drugs-in-america/?slreturn=20221021163553>)


⁴ <https://nutritionequity.org/wp-content/uploads/sites/12/2018/05/mnea-factsheet-sbs.pdf>

Timelines & Status: Orphan/Rare Disease Studies—Additional IIT POC Data Expected Throughout 2025

ONGOING MVID TRIALS & DEVELOPMENT TIMELINE

Indication: Pediatric MVID & SBS-IF
Location: Sheikh Khalifa Medical City, UAE
Number of Patients: 6
Trial Type: Unblinded investigator-initiated trial (IIT)
Principal Investigator: Dr. Mohamad Miqdady
Trial Status: Continuing to enroll


Indication: Pediatric MVID
Trial Type: Company’s double blind, placebo-controlled trial
Number of Patients: 6-8
Orphan Drug Designation in US and EU
Trial Status: Continuing to enroll



ONGOING SBS-IF TRIALS & DEVELOPMENT TIMELINE

Indication: Adult SBS-IF
Location: Cleveland Clinic, US
Number of Patients: 6
Trial Type: Unblinded investigator-initiated trial (IIT)
Principal Investigator: Dr. Lindsey Russell
Trial Status: Continuing to enroll

Indication: SBS-IF
Trial Type: Company’s double blind, placebo-controlled trial
Number of Patients: 18
Orphan Drug Designation in US and EU
Trial Status: Continuing to enroll



Increasing Market Value: Progression from Supportive Care to Impact on Outcome/Cost of Care to Treatment Modifying

Indication	# of Competitors	Market Size/Potential
HIV-related diarrhea	0	Jaguar estimates the U.S. market revenue potential for Mytesi® to be ~\$30-\$50 million in gross annual sales
Cancer therapy-related diarrhea (CTD)	0	Projected to be 2.0 million new cancer cases in US in 2024 ¹ Annual US breast cancer incidence >315,000; ² prevalence ~4 mm ³ Comparable supportive care (CINV) global market projected to reach \$5.1 billion by 2033 ⁴
Short bowel syndrome (SBS) with intestinal failure / Microvillus inclusion disease (MVID), a congenital diarrheal disorder (CDD)	0	~Global SBS market projected to reach \$6.4 billion by 2030 , growing at a CAGR of 21.6% from 2024 to 2030 ⁵ (doesn't include potential contribution from crofelemer's novel mechanism of action)
IBS - diarrhea predominant (IBS-D)	2	~15% of adult population Most IBS products have estimated revenue potential >\$1.0 billion ⁶
Symptomatic relief and treatment of diarrhea from cholera and other pathogens	0	*Potential opportunity for Priority Review Voucher (PRV) PRVs are transferable, and in past transactions by other companies have sold for values ranging from \$67 million to \$350 million ⁷

¹ American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.

² <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acf.pdf>

³ Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;1-23

⁴ <https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/>

⁵ <https://www.globenewswire.com/news-release/2025/02/12/3024819/28124/en/Growth-Trends-in-the-Short-Bowel-Syndrome-SBS-Market-2025-2030-Growth-of-Home-Healthcare-Specialty-Clinics-and-Telemedicine-Strengthens-Business-Case-for-SBS-Treatments.html>


⁶ <https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2021-Results-LINZESS-linaclotide-Achieves-Blockbuster-Status-as-U.S.-Net-Sales-Exceed-1-Billion-in-2021/default.aspx>;

Rodman & Renshaw estimate peak annual sales of Synergy Pharmaceuticals' Trulance at \$2.3 bn in 2021 (Source: <https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9224181/analyst-synergy-pharma-could-achieve-sustainable-profit>)

⁷ <https://www.pharmaceutical-technology.com/features/switching-sales-investigating-the-financial-impacts-of-fdas-priority-vouchers>

How Crofelemer Works

- Crofelemer is a non-opioid that works differently from other treatments for GI dysfunction



With crofelemer, it's about waterflow

Crofelemer normalizes waterflow in the GI tract
Less water flowing into your GI tract = less watery diarrhea = greater nutrient absorption opportunity



Crofelemer acts locally in the GI tract




Opioid medicines (e.g., Imodium, loperamide) work by slowing down your GI tract, i.e., opioid constipation risk



Crofelemer is a non-opioid, non-antibiotic, non-addictive drug approved in the US for a chronic use

Mechanism of Action



References: 1. Brenchley JM, Douek DC. *Mucosal Immunol.* 2008;1(1):23-30. 2. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals, Inc; 2020. 3. Tradtrantip L, Namkung W, Verkman AS. *Mol Pharmacol.* 2010;77(1):69-78. 4. Holodniy M, Koch J, Mistal M, et al. *Am J Gastroenterol.* 1999;94(11):3267-3273.

Emotional Support Program—Canalevia-CA1: Conditionally Approved for CID

- Mission: Bring Canalevia approval to general diarrhea in all dogs
- Possibility of approval of Canalevia for treatment of general diarrhea in dogs in EU based on statistically significant data from completed study
- Bus dev opportunity for commercial collaboration



Canalevia®-CA1 (Crofelemer): A New Standard of Care For Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs Launched April 2022

Approximately 1 in 4 dogs will, at some stage in their life, develop neoplasia. Almost half of dogs over the age of 10 will develop cancer. ~6 million new cancer diagnoses are made in dogs each year in the U.S.¹

Pet owners' willingness to pay for life saving treatments and procedures increases with patient comfort.

~40% of treated dogs may have their chemotherapy reduced, changed, or discontinued due to diarrhea

Similar dynamics to human specialty market, but with greater correlation between gross and net revenue with pet owner paying out of pocket.

Conditional approval in dogs is similar to orphan drug designation in humans.




¹ <https://www.avma.org/resources/pet-owners/petcare/cancer-pets>

A Unique Opportunity in US Animal Health

Acute Non-Infectious Diarrhea in dogs (ANID): An Unmet Medical Need

- Gastrointestinal disorders in dogs are the most common reason for a veterinary visit¹
- 90 million Dogs in the US²
- Approximately 14.9%³ of dogs present with acute diarrhea annually
- 85% of the acute diarrhea is non-infectious (ANID)
- No CVM-approved drugs for treatment of ANID in dogs
- Most prescribed medications for ANID are antibiotics, which contradicts AVMA recommendation to reduce reliance on antimicrobials for treating diarrhea



¹ <https://news.nationwide.com/most-common-conditions-that-prompt-veterinary-visits-2024/>

² <https://www.avma.org/resources-tools/reports-statistics/us-pet-ownership-statistics>

³ <https://pmc.ncbi.nlm.nih.gov/articles/PMC7132454/#bib0065>

⁴ <https://www.chewy.com/canalevia-ca1-crofelemer-tablets-dogs/dp/741990>


Targeted Mode of Action for the Active Ingredient in Canalevia

Paradigm-shifting mode of action differentiates Canalevia from current antibiotic and antimotility regimens

“By providing a targeted solution that improves gastrointestinal health, this product offers an alternative to metronidazole in this era of microbial stewardship.”


-Craig Clifford, DVM, MS, DACVIM (Oncology)

- During diarrhea events, intestinal fluid secretion is driven by active trans-epithelial chloride hypersecretion. Crofelemer acts locally to **normalize** the secretion of chloride into the small intestine, and consequently resolves the diarrhea without causing constipation.




Normal

Active transport of Cl^- by CFTR and CaCC channels is the final step of fluid secretion by intestinal epithelial cells in the GI tract, allowing normal stool formation.




Diarrhea

During diarrhea events, inflammation triggers hyperactive Cl^- channels and the accompanying high-volume water loss.



Crofelemer

A novel allosteric modulator of CFTR and CaCC, crofelemer acts by regulating the gating of hyperactive Cl^- channels, normalizing channel activity, and restoring the water balance in the GI tract.



Magdalena Biosciences

Program to support the discovery and development of **novel psychoactive medicines derived from plants** for mental health and CNS disorders


- Leverage Company's proprietary library of ~2,300 plants and ~3,500 plant extracts with ethnomedicinal investigation
- Seeking next generation first-in-class agents, novel mechanisms of action, disease modifying agents

Eight key agents being pursued by psychedelic-focused companies:

- LSD and derivatives
- Psilocybin and derivatives (mushrooms in the genus *Psilocybe*)
- Iboga and derivatives
- Toad sections from *Bufo Alvarius* 5-MeO-DMT
- MDMA (referred to as ecstasy or Molly)
- Ketamine
- Mescaline and derivatives (peyote is most well-known source but not only source)
- DMT and derivatives (most well-known source is the *Banisteriopsis* and *Psychotria viridis* mixture known as Ayahuasca)



Picralima nitida plant, the source of the active ingredient alstonine



Peyote (*Lophophora williamsii*), a source of mescaline

Jaguar and Filament Health, with Funding from One Small Planet, Form Joint Venture *Magdalena Biosciences* to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses


Magdalena currently valued at US\$5.0 million based on initial funding of US\$1.0 million from One Small Planet

- Magdalena Biosciences leverages Jaguar's proprietary 2300 medicinal plant library
- Jaguar currently owns ~40% of Magdalena
- **Goal of Collaboration:** To extend the botanical drug development capabilities of Jaguar to:
 - Develop pharmaceutical-grade, standardized drug candidates for mental health disorders
 - **Partner with a potential future licensee** to develop and commercialize these novel plant-based drugs



Three IND candidates: ADHD, schizophrenia, anxiety, APPETITE SUPPRESSION

Net Revenue: Net Q3 2025 Revenue of ~\$3.1 Million Increased ~4% Versus Net Q2 2025 Revenue of ~\$3.0 Million & Equaled Net Q3 2024 Revenue



Recent & Anticipated Catalysts – Financial, Clinical & Commercial

- **Jan 2025:** Initiation of crofelemer IIT in Abu Dhabi in pediatric patients with MVID or SBS-IF
- **Q1 2025:** FPFV for crofelemer IIT at Cleveland Clinic in adult SBS-IF patients
- **Q2 2025:** Initiation by Napo Therapeutics of global placebo-controlled study of crofelemer in MVID patients
- **Apr 26, 2025:** Presentation of initial POC IIT results for crofelemer for SBS-IF and MVID at Elite Ped-GI Congress; availability of first POC IIT result for crofelemer for SBS-IF and MVID; supports potential qualification for EMA's PRIME program and FDA's Breakthrough Therapy program, and early patient access in specific EU countries
- **May 2025:** Meeting with FDA to obtain clarity regarding possible pathways to make crofelemer available as efficiently as possible to breast cancer patients for CTD
- **Nov 8, 2025:** Presentation of initial POC IIT results for crofelemer for MVID and SBS-IF at NASPGHAN
- **H1 2026:** Initiation of additional crofelemer IIT for SBS – change formulation
- **H1 2026:** Business development deal for development and commercialization of extension of Canalevia CA-1 prescription drug candidate for general diarrhea in dogs
- **H1 2026:** Business development deal for rare disease and/or CTD – non-dilutive funding
- **H1 2026:** Jaguar mental health-focused joint venture Magdalena Biosciences to initiate clinical development for botanical drug candidate
- **H1-H2 2026:** End of placebo-controlled trials and results of crofelemer in MVID
- **H1 2027:** End of placebo-controlled trial and results of crofelemer in SBS-IF



Jaguar/Napo Pharmaceuticals Executive Management Team

Name / Title	Experience
Lisa Conte Founder & CEO	30+ years of industry experience - Obtained first anti-secretory human product FDA approval - Board of Directors of Healing Forest Conservancy - Raised over \$400 mm for the Company
Carol Lizak, MBA Chief Financial Officer	20 years corporate controllership and financial planning and analysis experience under U.S. GAAP & IFRS 10+ years with public companies including foreign subs (5 years in biopharma)
Steven King, PhD Chief Sustainable Supply, Ethnobotanical Research & IP Officer	- Served as head of sustainable supply, ethnobotanical research & IP: 1989-2020 - Board of Directors of Healing Forest Conservancy
Pravin Chaturvedi, PhD Chief Scientific Officer Chair of Scientific Advisory Board	25+ years drug development experience - Co-Founded Scion, IndUS and Oceanyx Pharmaceuticals - Successfully developed Mytesi® (first pivotal adaptive design) and 7 pharmaceutical products
Massimo Radaelli, PhD President of Jaguar International & CEO of Napo Therapeutics	- European pharmaceutical industry leader and entrepreneur with 35+ years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases - Founded Noventia Pharma in 2009 and serves as its Chairman, President, and CEO; founded Pint Pharma Group and Ferrer Italia, was co-founder of a Dupont-Merck JV Italian subsidiary
Karen J. Brunke, PhD Executive VP, Corporate & Business Development	30+ years experience in research, operations and BD in pharma/biotech - Primary responsibility in deals with MedImmune, Astellas; closed GSK deal - Successfully developed GMOs at Sandoz while Research Director
David Sesin, PhD Chief Manufacturing Officer	- Pharmaceutical scientist with experience from drug discovery through manufacturing - Developed crofelemer manufacturing process
Jonathan Wolin, JD, MBA Chief of Staff, Chief Compliance Officer & General Counsel	Extensive experience providing legal advice and guidance to public and private companies in the healthcare and biotechnology industries
Ian H. Wendt, MBA Chief Commercial Officer	Has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry over past 25 years
Ismaila Sougoufara Chief Accounting Officer and VP Finance	10+ years of assurance (audit) and consulting (transaction advisory services) experience with Big Four audit and advisory firms (E&Y and RSM) 6 years of management consulting with global consulting firms (Korn Ferry) in the areas of M&A, finance transformation, core and commercial finance, FP&A, business partnerships, technical accounting, system implementations, risk and corporate compliance. 5 years leading Jaguar Health's accounting and finance activities

Investment Highlights

Mytesi (Crofelemer): FDA-Approved Human Drug

- Only FDA-approved diarrhea treatment that's been studied specifically in adults with HIV / AIDS
- Supply chain in place
- Positive EBITDA

Planned Crofelemer Expansion

- **Progression from supportive care to impact on outcome/cost of care to treatment modifying**
- CTD – target sNDA filing for adult breast cancer patients on targeted therapy based on statistically significant Phase 3 results in this prespecified subgroup
- Intestinal failure – SBS and MVID – 4 clinical catalysts
- Early patient access, PRIME, and Breakthrough Therapy designation pathways

Strategic Focus on Rare Diseases

- Orphan drug designation application submitted for breast cancer with metastasis to brain
- Orphan Drug Designation US and EU: Microvillus inclusion disease (MVID)
- Orphan Drug Designation US and EU: Short bowel syndrome (SBS)
- **Reduction in TPN/PS paradigm-shifting**
- POC data catalyst for collaborations with rare disease companies

Canalevia-CA1 for Chemotherapy-Induced Diarrhea (CID) in Dogs

- Canalevia-CA1 FDA conditionally approved December 2021
- Estimated 6 million new cancer diagnoses in dogs each year in US; 25-40% experience diarrhea
- CID is predictive of human situation
- Potential for bus dev relationship to expand indication to general acute diarrhea in companion animals

Strategic Partnerships

- Unencumbered global commercial rights to Mytesi/crofelemer pipeline
- Magdalena Biosciences leveraging proprietary 2,300-plant ethnobotanical database

Strong Management Team

- Key management has been with the team for >20 years
- Recent investment by CEO, C suite team members, and board members

Proprietary Position

- ~195 patents (majority do not expire until 2027 - 2031) and ~56 patents pending
- Sustainable supply of commercial scale of raw material sourcing
- Botanical guidance protection – no practical generic pathway



JAGX Analyst Coverage

Firm	Analyst	Phone or Email	Website
First Berlin Securities Brokerage	Christian Orquera	c.orquera@firstberlin.com	https://firstberlin.com
Ladenburg Thalmann & Co. Inc.	Jeffrey S. Cohen	561.620.2049	https://www.ladenburg.com
Ladenburg Thalmann & Co. Inc.	Destiny A. Hance	561.620.2104	https://www.ladenburg.com



Jaguar Health, Inc. (NASDAQ: JAGX)

Contact:

hello@jaguar.health

